| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1002146602 |
| P356 | DOI | 10.2165/00128072-200204070-00005 |
| P698 | PubMed publication ID | 12083974 |
| P50 | author | Manjunath P Pai | Q57339551 |
| P2093 | author name string | Keith A Rodvold | |
| Donna M Kraus | |||
| P2860 | cites work | An emotional-based medicine approach to monitoring once-daily aminoglycosides | Q73327945 |
| National survey of extended-interval aminoglycoside dosing | Q73560643 | ||
| Pharmacokinetics of once-daily dosing of gentamicin in neonates | Q73582979 | ||
| Single daily doses of aminoglycosides | Q73882958 | ||
| Gentamicin-induced bilateral vestibular hypofunction | Q74236096 | ||
| Once- versus twice-daily gentamicin dosing in neonates >/=34 Weeks' gestation: cost-effectiveness analyses | Q74525859 | ||
| The pharmacodynamics of aminoglycosides | Q74802269 | ||
| Pharmacokinetics of once-daily gentamicin dosing in pediatric patients | Q77050522 | ||
| The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis | Q77075542 | ||
| An extended interval dosing method for gentamicin in neonates | Q77322019 | ||
| Once daily gentamicin dosing in neonates | Q77758812 | ||
| A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients | Q28325426 | ||
| The aminoglycosides | Q28375494 | ||
| Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs | Q30501061 | ||
| Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? | Q33545113 | ||
| Once-daily aminoglycoside administration in gram-negative sepsis. Economic and practical aspects | Q33569075 | ||
| Some international approaches to aminoglycoside monitoring in the extended dosing interval era. | Q33708718 | ||
| Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria | Q33976467 | ||
| Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity | Q33977062 | ||
| Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit | Q34122125 | ||
| Aminoglycoside adaptive resistance: importance for effective dosage regimens | Q34277787 | ||
| A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses | Q34389944 | ||
| A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine | Q34461054 | ||
| Pharmacokinetics and antibacterial activity of daily gentamicin | Q35066606 | ||
| Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis | Q35259780 | ||
| Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia. | Q35262273 | ||
| Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule | Q35574233 | ||
| Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children | Q35885240 | ||
| First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use. | Q36752618 | ||
| Daily dosage of aminoglycosides. | Q39447325 | ||
| Experience with a once-daily aminoglycoside program administered to 2,184 adult patients | Q39779327 | ||
| Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer. | Q40646260 | ||
| Once daily ceftriaxone plus amikacin vs. three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer. Writing Committee for the International Collaboration on Antimicrobial Treatment of Febrile Neutropenia i | Q40653024 | ||
| Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation | Q40749278 | ||
| Post-antibiotic effects in experimental infection models: relationship to in-vitro phenomena and to treatment of infections in man. | Q40827402 | ||
| Once-daily versus multiple-daily dosing of aminoglycosides | Q40982176 | ||
| Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis | Q40988370 | ||
| Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. | Q41058829 | ||
| Aminoglycoside nephrotoxicity. | Q41319367 | ||
| Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review | Q41463791 | ||
| Once-daily dosing of aminoglycosides: review and recommendations for clinical practice | Q41530531 | ||
| Once-daily gentamicin dosing in newborn infants | Q41669362 | ||
| Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections | Q41962121 | ||
| Once daily antibiotic regimen in paediatric oncology | Q42011952 | ||
| Single or multiple daily doses of aminoglycosides: a meta-analysis | Q42145555 | ||
| A comparison of two amikacin dosing regimens in paediatric surgical patients | Q42545727 | ||
| Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections | Q42647487 | ||
| Influence of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man | Q43467285 | ||
| Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model | Q43617611 | ||
| Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration | Q44483617 | ||
| Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients | Q44484329 | ||
| Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli | Q44772163 | ||
| Adaptation in neonatology of the once-daily concept of aminoglycoside administration: evaluation of a dosing chart for amikacin in an intensive care unit | Q44886328 | ||
| Once versus twice daily amikacin in neonates: prospective study on toxicity | Q46381595 | ||
| Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia | Q46611376 | ||
| The pharmacokinetics of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens | Q46960940 | ||
| Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring | Q47832029 | ||
| Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity | Q48390110 | ||
| A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. | Q50509585 | ||
| A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. | Q50509590 | ||
| Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections. | Q50517787 | ||
| In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. | Q52429639 | ||
| Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections | Q54297609 | ||
| Adaptive resistance to aminoglycoside antibiotics from first-exposure down-regulation. | Q54319060 | ||
| Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa. | Q54355199 | ||
| Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. The International Antimicrobial Therapy Cooperative Group of t | Q64132922 | ||
| Single daily dose amikacin in paediatric patients with severe Gram-negative infections | Q67920887 | ||
| Once-daily dosing decreases renal accumulation of gentamicin and netilmicin | Q69936275 | ||
| In vivo postantibiotic effect in a thigh infection in neutropenic mice | Q70370760 | ||
| Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients | Q71765938 | ||
| Mega-analysis of meta-analysis: an examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials | Q71842921 | ||
| National survey of once-daily dosing of aminoglycoside antibiotics | Q71928743 | ||
| Gentamicin once-daily versus thrice-daily in children | Q72259506 | ||
| Once daily dosing of netilmicin in neonatal and pediatric intensive care | Q72726142 | ||
| Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside | Q73167979 | ||
| Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients | Q73208219 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 469-484 | |
| P577 | publication date | 2002-01-01 | |
| P1433 | published in | Pediatric Drugs | Q15767256 |
| P1476 | title | Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients | |
| P478 | volume | 4 |
| Q33753500 | Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). |
| Q36191093 | Evaluation of serum concentrations achieved with an empiric once-daily tobramycin dosage regimen in children and adults with cystic fibrosis |
| Q40751575 | Extended-interval gentamicin administration in neonates: a simplified approach |
| Q38051316 | Once daily dosing of aminoglycosides in pediatric cystic fibrosis patients: a review of the literature |
| Q47595207 | Once-daily intramuscular amikacin for outpatient treatment of lower urinary tract infections caused by extended-spectrum β-lactamase-producing Escherichia coli in children |
| Q44766864 | Optimized antimicrobial dosing strategies: a survey of pediatric hospitals |
| Q35623060 | Pharmacodynamics and dosing of aminoglycosides |
| Q34923469 | Population pharmacokinetics of gentamicin and dosing optimization for infants |
| Q93609063 | References |
| Q87393334 | Section 3: Prevention and Treatment of AKI |
| Q44891914 | Use of 4-mg/kg/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease |
Search more.